Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Withdrawal of Dupilumab in Severe Asthma
NCT06818019Phase 4Recruiting
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab in severe asthma, sponsored by Centre hospitalier universitaire de Toulouse. Started Dec 2025; status: recruiting.
02
Drugs
03
Conditions
severe asthma
Beyond the preview
Go deeper on NCT06818019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06818019.